Home » Stocks » Stoke Therapeutics

Stoke Therapeutics, Inc. (STOK)

Stock Price: $23.40 USD 0.35 (1.52%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 771.57M
Revenue (ttm) n/a
Net Income (ttm) -37.62M
Shares Out 32.97M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $23.40
Previous Close $23.05
Change ($) 0.35
Change (%) 1.52%
Day's Open 23.09
Day's Range 22.94 - 23.77
Day's Volume 90,789
52-Week Range 15.82 - 39.04

More Stats

Market Cap 771.57M
Enterprise Value 560.07M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 32.97M
Float 8.11M
EPS (basic) -2.23
EPS (diluted) -2.66
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.13M
Short Ratio 28.39
Short % of Float 25.87%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.55
Revenue n/a
Operating Income -41.09M
Net Income -37.62M
Free Cash Flow n/a
Net Cash 211.49M
Net Cash / Share 6.41
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.86%
ROE -23.97%
ROIC -2,898.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$37.40*
(59.83% upside)
Low
30.0
Current: 23.40
High
46.0
Target: 37.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-35.68-12.78-5.55
Net Income-32.33-12.52-5.56
Shares Outstanding17.970.710.67
Earnings Per Share-1.80-17.65-8.29
Operating Cash Flow-31.06-10.96-5.56
Capital Expenditures-1.63-0.93-0.11
Free Cash Flow-32.69-11.89-5.67
Cash & Equivalents2231061.85
Net Cash / Debt2231061.85
Assets2291082.44
Liabilities4.322.473.73
Book Value224105-1.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Stoke Therapeutics, Inc.
Country United States
Employees 56
CEO Edward M. Kaye

Stock Information

Ticker Symbol STOK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: STOK

Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.